Antigen selection for vaccination considers several factors, such as high immunogenicity to evoke a robust and persistent response from CD4 helper and CD8 cytotoxic T cells, as well as tumor-specific or tumor-exclusive expression of the antigen, to ensure effective targeting and minimize off-target toxicity [396]. The gene discussed is CD8A; the disease is neoplasm.